Skip to main content
. 2022 Apr 21;3(5):100323. doi: 10.1016/j.jtocrr.2022.100323

Table 1.

Demographic, Clinical, and Treatment Characteristics

Characteristic N (%)
p Value
Total AD No AD
N 48 16 32
Mean age at diagnosis (y) (SD) 54 (15) 51 (17) 55 (14) 0.37
Male sex 30 (63) 8 (50) 22 (69) 0.21
Race
 Black 0 (0) 0 (0) 0 (0) 0.46
 Native American or Alaskan Native 1 (2.1) 0 (0) 1 (3.1)
 Asian 22 (46) 10 (63) 12 (38)
 White 18 (38) 5 (31) 13 (41)
 Native Hawaiian or Other Pacific Islander 2 (4.2) 0 2 (6.3)
 Other 5 (10) 1 (6.3) 4 (13)
WHO classification
 Thymoma 28 (58) 13 (81) 15 (47) 0.01
 Thymic carcinoma 18 (38) 2 (13) 16 (50)
 Not defined 2 (4) 1 (6) 1 (3)
Masaoka-Koga stage at diagnosis
 I 2 (4.2) 1 (6.3) 1 (3.2) 0.81
 II 2 (4.2) 1 (6.3) 1 (3.2)
 III 9 (19) 3 (19) 6 (19)
 IV 30 (63) 8 (50) 22 (69)
 Not defined 5 (10) 3 (19) 2 (6.3)
Total thymectomy 29 (60) 10 (63) 19 (59) 0.84
Radiation therapya 36 (75) 11 (69) 25 (78) 0.48
Systemic treatment for thymic neoplasm 46 (96) 15 (94) 31 (97) 0.61
Median number of systemic treatments (range) 3.0 (0–8) 3.0 (0–5) 3.0 (0–8) 0.83

Note: Data are expressed as number and percentage, n (%) except where otherwise stated. Bold values indicate statistical significant.

AD, autoimmune disease.

a

Indications for radiation therapy included the following: adjuvant, definitive, oligometastatic, and palliative.